ANTIBODIES THAT BIND BOTH IL-17A AND IL-17F AND METHODS OF USING THE SAME
The present invention relates to blocking, inhibiting, reducing, antagonizing or neutralizing the activity of IL-17A and IL-17F. IL-17A and IL-17F are cytokines that are involved in inflammatory processes and human disease. The present invention includes antibodies that bind both IL-17A and IL-17F, as well as methods of using the same in inflammation.
1 . An isolated, cross-reactive monoclonal antibody or antigen-binding fragment thereof that binds to both IL-17A (SEQ ID NO:2) and IL-17F (SEQ ID NO:4), wherein said antibody binds to a discontinuous IL-17F epitope comprising amino acid residues 105-109 and 147-152 of SEQ ID NO:4 and a discontinuous IL-17A epitope comprising amino acid residues 107-111 and 149-154 of SEQ ID NO:2; and wherein said antibody reduces the pro-inflammatory activity of both IL-17A and IL-17F.
2 . The antibody of claim 1 , wherein the antibody is selected from the group consisting of a murine antibody, a chimeric antibody, a humanized antibody, and a human antibody.
3 . The antibody of claim 1 , wherein the antigen-binding fragment is a single chain antibody.
4 . The antibody of claim 1 , wherein the antigen-binding fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv antibody fragments.
5 . A composition comprising:
the antibody or antigen-binding fragment of claim 1 ; and
a pharmaceutically acceptable vehicle, carrier, or excipient.